指南与共识湿疹皮炎与荨麻疹

特应性皮炎临床体征测量:HOME-CP共识声明

Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement.
指南 / 共识 · JAMA Dermatol · 2024-01-01

该共识由HOME临床实践倡议制定,旨在推荐用于临床实践的特应性皮炎(AD)临床体征测量工具。通过系统综述和共识会议(共识定义为分歧<30%),推荐EASI、SCORAD、objective SCORAD等工具,认为这些工具效度可行,有助于标准化体征记录和疗效评估。

要点

  • 推荐EASI、SCORAD和objective SCORAD用于临床实践测量AD体征。
  • 改良EASI和SGA×BSA也被推荐。
  • EASI、vIGA及IGA联合BSA测量达成共识并采纳。

核心结论

  • HOME-CP共识声明建议临床评估和记录AD体征时,可选用多种有效且可行的工具,以适应不同实践需求。

研究设计与样本

  • 采用混合方法设计,包括系统综述和定性共识方法,遵循预设路线图。
  • 共识定义为分歧小于30%。

主要发现

  • 更新的系统综述发现,EASI、SCORAD和objective SCORAD是唯一在所有评估的测量属性中均表现出足够性能的工具。
  • 改良EASI和Signs Global Assessment × Body Surface Area工具也被推荐。
  • EASI、Validated Investigator Global Assessment和Investigator's Global Assessment乘以或同时测量体表面积在标准上达成共识并被采纳。

关键数值与推荐

  • 推荐EASI、SCORAD、objective SCORAD、改良EASI和SGA×BSA用于临床实践测量AD临床体征。
  • EASI、vIGA和IGA(乘以或同时测量BSA)达成共识并被采纳。

临床怎么用

  • 临床医生可根据具体实践需求选择推荐工具中的一种来评估和记录AD体征。
  • 使用这些工具应能改善和标准化体征严重程度的记录,帮助判断治疗效果,促进临床有效性证据生成,并增强价值医疗的实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical Practice initiative aims to identify a list of validated, feasible, outcome measurement instruments recommended to measure atopic dermatitis (AD) in the clinical practice setting. The clinical practice set is a list of instruments that clinicians can pick and choose from to suit their needs in the context of clinical care. OBJECTIVE: To recommend instruments to measure clinical signs of AD in clinical practice. EVIDENCE REVIEW: Following the predefined roadmap, a mixed methods design was implemented and incorporated systematic reviews and qualitative consensus methods. Previous systematic reviews identified few clinical signs instruments with sufficient validation for recommendation. An updated systematic review evaluating the validity of clinical signs instruments informed an international meeting to reach consensus on recommended instruments to measure AD clinical signs in clinical practice. Consensus was defined as less than 30% disagreement. An in-person consensus exercise was held in Montreal, Canada, on October 16, 2022. The 34 attendees included patient and patient advocate research partners, health care professionals, researchers, methodologists, and industry representatives. FINDINGS: The updated systematic review found that the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis, and objective Scoring Atopic Dermatitis were the only instruments that demonstrated sufficient performance in all assessed measurement properties. The modified EASI and Signs Global Assessment × Body Surface Area instruments were also recommended. The EASI, Validated Investigator Global Assessment, and Investigator's Global Assessment multiplied by or measured concurrently with a body surface area measure achieved consensus in criteria and were adopted. CONCLUSIONS AND RELEVANCE: This consensus statement by the Harmonising Outcome Measures for Eczema initiative suggests that when assessing and documenting clinical signs of AD, there are several valid and feasible instruments that can best fit a clinician's specific practice needs. These instruments should improve and standardize the documentation of signs severity, help determine the effect of treatment, facilitate the generation of clinical effectiveness evidence, and enhance the implementation of value-based health care.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Jacobson ME, Leshem YA, Apfelbacher C, et al. Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement. JAMA Dermatol. 2024. PMID: 38776110. doi:10.1001/jamadermatol.2024.1162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。